Epcoritamab (GEN3013; DuoBody-CD33CD20) to induce complete response in patientswith relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose esca-lation data and efficacy results from a phase I/II trial
Abstract No : 8009
Abstract Type : Oral Abstract Session
Indication : NHL (DLBCL/FL)
Intervention : Epcoritamab
Company : Genmab
Technology : Bispecefic Antibody
Results:
As of 8 Jan 2020, 41 pts with median age of 66 (range: 21–82) were enrolled. Most pts had DLBCL/HGBCL (73%) or FL (20%) and received a median (range) of 3 (1–6) and 5 (2–18) prior lines of treatment. No DLTs were observed (median follow-up: 4.7 mo; range: 3.7– 5.6). MTD has not been reached. Most common TEAEs (>35%) were pyrexia (71%), fatigue (46%), and injection site reaction (39%; all Gr 1). AEs of special interest included cytokine release syndrome (59%; all Gr 1/2; all resolved) and cytokine release-related decreased CARTOX-10 score (n=1). There was no clinical tumor lysis syndrome or treatment-related deaths. Treatment is ongoing in 13 pts. Anti-tumor activity was observed at minimal efficacy threshold (based on PK modelling) for DLBCL/HGBCL and FL (Table). Complete dose escalation data and RP2D will be presented.
Conclusion:
SC epcoritamab continues to demonstrate a favorable safety profile across all doses with no ≥Gr 3 CRS and no DLTs. Dose escalation data show improved efficacy as doses reach above the modeled predicted exposure threshold, inducing CRs in heavily pretreated DLBCL pts. All pts achieving CRs remain in remission
Commentary:
Pcoritamab demonstrates efficacy (ORR 50%) in R/R patients who failed multiple previous line of therapies.
Refer to Diffuse Large B-Cell Lymphoma Market report for detailed Insights.
